THAW: The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery

Sponsor
Ruby Grewal (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04907812
Collaborator
(none)
50
1
2
12
4.2

Study Details

Study Description

Brief Summary

Hand edema following hand surgery is a common yet devastating side effect that can lead to early stiffness, prolonged rehabilitation and diminished function. These factors can reduce a patient's quality of life; mounting to an overall delay in recovery, return to work and daily activities. Conventional edema therapy includes cryotherapy, external compression, active and passive exercises and various types of massage. However, there is little evidence to suggest these modalities are effective. Tranexamic acid (TXA) is an antifibrinolytic that has been used in surgical disciplines for decades to aid in reducing intraoperative blood loss and consequent transfusions. Recently, the use of TXA for curbing post-operative edema and ecchymosis has shown promising results, however, its use in hand surgery has not been studied.

Condition or Disease Intervention/Treatment Phase
  • Drug: Tranexamic acid
  • Procedure: Surgery
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A Prospective, Randomized Controlled, Double-Blinded Pilot StudyA Prospective, Randomized Controlled, Double-Blinded Pilot Study
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery (THAW): A Prospective, Randomized Controlled, Double-Blinded Pilot Study
Anticipated Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tranexamic Acid (TXA)

Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery

Drug: Tranexamic acid
Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery

Procedure: Surgery
This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints <50 contracture ii. PIP joints <40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved

Placebo Comparator: Standard of Care (SOC)

Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery

Procedure: Surgery
This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints <50 contracture ii. PIP joints <40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints >50 degree contracture ii. PIP Joints >40 degrees contracture b. >2 fingers involved

Outcome Measures

Primary Outcome Measures

  1. Adherence to protocol [12 weeks]

    Assess number of patients who receive hand volume measurements at all designated time intervals. The outcome goal will be 90%

  2. Treatment Completion Rate [12 weeks]

    Asses proportion of patients who correctly receive the intervention as per the protocol. The outcome goal will be 90%

  3. Retention Rate [12 weeks]

    Proportion of participants to complete the study protocol and associated follow up. The outcome goal will be an 80% retention rate

  4. Recruitment rate [12 weeks]

    Number of patients recruited to the study per month. The outcome goal will be 5 patients per month

Secondary Outcome Measures

  1. Hand volume [12 weeks]

    Hand volume will be assessed using two validated methods; water displacement and figure of eight measurement.

  2. Patient-reported pain scores [12 weeks]

    Patient Reported Wrist and Hand Evaluation (PRWHE). The PRWHE allows patients to rate their levels of hand and wrist pain and disability. It is rated on a 0-100 scale. A higher score in the scale denotes a worse outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients >18 years old undergoing distal radius fracture open reduction and internal fixation through a volar approach at St. Joseph's hospital in London, Ontario

  • All patients >18 years old undergoing open fasciectomy for Dupuytren's disease at St. Joseph's hospital in London, Ontario

Exclusion Criteria:
  • Revision surgery

  • Distal radius fractures treated with additive or alternative approaches and fixation to the volar approach

  • Known history of lymphedema or lymph node dissection on either upper extremity

  • Known allergic reaction to TXA

  • Cardiovascular problems (history of myocardial infraction, angina, and atrial fibrillation)

  • Cerebrovascular conditions (history of previous stroke)

  • Thromboembolic disorders (history of deep vein thrombosis [DVT] or pulmonary embolism [PE]), clotting disorders)

  • Known seizure disorder

  • Currently on dialysis

  • Current pregnancy or breastfeeding

  • Current use of hormone contraception

  • Unable to read consent and patient surveys related to the study in English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lawson Health Research Institute London Ontario Canada

Sponsors and Collaborators

  • Ruby Grewal

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ruby Grewal, Co-director of the clinical research lab within the Roth | McFarlane Hand and Upper Limb Center (HULC), Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT04907812
Other Study ID Numbers:
  • 116724
First Posted:
Jun 1, 2021
Last Update Posted:
Jun 1, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Ruby Grewal, Co-director of the clinical research lab within the Roth | McFarlane Hand and Upper Limb Center (HULC), Lawson Health Research Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2021